Vascarta Inc.
Vascarta Inc. is a pharmaceutical company that has developed a patented topical/transdermal delivery platform aimed at improving the bioavailability of drugs, particularly curcumin, a compound known for its anti-inflammatory and antioxidant properties. The company focuses on addressing unmet medical needs through innovative formulations that enhance therapeutic efficacy and patient outcomes.
Vascarta Inc.
Town & Country Pharmacy, 535 East Crescent Ave, Ramsey, NJ 07446
What We Do
A patented formulation designed to enhance the bioavailability and therapeutic potential of curcumin through transdermal delivery, significantly improving its absorption and effectiveness compared to traditional methods.
A topical/transdermal gel formulation of curcumin that solubilizes curcumin over 100 times more than traditional topicals, allowing for deeper skin penetration and enhanced therapeutic effects.
Regenerative Medicine
Application Area
Psychological and Cognitive Health and Performance
Routes of Administration
Services
Key People
Chairman of the Board, CEO & President
Chief Scientific Officer, Board member
Executive Vice President Corporate Development, Board member
Executive Vice President, Commercialization
Consultant
Funded Projects
MTEC Announces Awardees of 2016 Regenerative Medicine Research Projects
In partnership with the U.S. Army Medical Research & Materiel Command (USAMRMC), the Medical Technology Enterprise Consortium (MTEC) is pleased to announce the selectees in the initial round of research project awards issued under its February 29, 2016 Regenerative Medicine Request for Project Proposals. The projects listed at the bottom of this page were selected by the USAMRMC to receive funding as indicated.
News & Updates
An article discussing the innovative use of curcumin in Vascarta's formulations and its potential health benefits.
Vascarta has developed a patented topical/transdermal delivery system that significantly enhances the bioavailability of curcumin, improving its therapeutic potential.
Patent for Vascarta's method of enhancing the solubility and penetration of curcumin through the skin, published on November 1, 2022.
Patent for Vascarta's transdermal delivery technology, published on October 17, 2023.
Patent for Vascarta's transdermal delivery technology, published on October 17, 2023.
Patent for Vascarta's transdermal delivery technology, published on October 17, 2023.